Cancer Archives

cancer dna damage repair duke street bio parp

News and Trends 25 May 2022

Duke Street Bio enters stage with next-generation cancer therapies

The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […]

May 25, 2022 - 3 minutesmins - By Susannah Rodgers

News and Trends 13 May 2022

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […]

May 13, 2022 - 4 minutesmins - By Jim Cornall

In Depth 9 May 2022

Exosome Therapy: Borrowing from Nature’s Toolbox

In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […]

May 9, 2022 - 11 minutesmins - By Farhan Mitha

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […]

May 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 27 Apr 2022

Cancer Research UK Deploys €700M to Foster Oncology Startups

In a show of strength after an income squeeze during the Covid-19 pandemic, the charity Cancer Research UK has dedicated €711M (£600M) to setting up a new innovation arm and seed fund designed to speed up the commercialization of oncology innovation. For decades, Cancer Research UK (CRUK) has played a pivotal role in nurturing advances […]

April 27, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 6 Apr 2022

Immunocore Approvals Open Door for TCR Cancer Drugs

The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific drug based on a cancer-hunting protein called a T-cell receptor (TCR). These regulatory wins by the UK firm Immunocore pave the way for other treatments deploying TCRs. TCRs have become a hot topic in immuno-oncology. Many companies are developing cancer […]

April 6, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Mar 2022

Precision Medicine Startups Increase Focus on Data Access and Privacy

Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and ownership remains a key issue for many individuals. Sano Genetics is one of many firms driving precision medicine by creating a more mutually beneficial relationship between patients and pharma companies. The falling costs of DNA sequencing are leading to serious […]

March 31, 2022 - 4 minutesmins - By Anita Chakraverty

radiopharmaceutical treatments precirix jeito

News and Trends 17 Mar 2022

€80M Series B Establishes European Champion in Radiopharmaceuticals

Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel the local radiopharmaceutical scene by investing €80M in the Belgian firm Precirix. Europe has a long history of expertise in the development of radiopharmaceutical drugs. One of the pioneers in the field was Advanced Accelerator Applications (AAA) in France. AAA […]

March 17, 2022 - 4 minutesmins - By Jonathan Smith

norway cytovation cancer immuno oncology

News and Trends 26 Jan 2022

Norwegian Biotech Put on the Map with €18M Oncology Round

The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway’s biggest Series A rounds in life sciences. Historically, Norway’s biotech scene has not seen the kind of venture capital funding characteristic of health and biotech in the UK and US. However, Norwegian biotech is growing and has seen more successes than many […]

January 26, 2022 - 3 minutesmins - By Dan Samorodnitsky

News and Trends 22 Oct 2021

Gene-Edited T Cell Therapy Players Battle Safety Doubts

Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […]

October 22, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Duke Street Bio enters stage with next-generation cancer therapies

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Exosome Therapy: Borrowing from Nature’s Toolbox

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Tubulis Rides Investment Wave in ADCs with €60M Series B

Cancer Research UK Deploys €700M to Foster Oncology Startups

Immunocore Approvals Open Door for TCR Cancer Drugs

Precision Medicine Startups Increase Focus on Data Access and Privacy

€80M Series B Establishes European Champion in Radiopharmaceuticals

Norwegian Biotech Put on the Map with €18M Oncology Round

Gene-Edited T Cell Therapy Players Battle Safety Doubts

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!